- Home
- INCY
INCY
Incyte Corp.
as of 12-23-2025 3:45pm EST
$100.64
$0.07
-0.07%
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 17.0B | IPO Year: | 1993 |
| Target Price: | $94.94 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 5.90 | EPS Growth: | 3878.02 |
| 52 Week Low/High: | $53.56 - $109.28 | Next Earning Date: | 02-09-2026 |
| Revenue: | $4,813,105,000 | Revenue Growth: | 18.09% |
| Revenue Growth (this year): | 19.59% | Revenue Growth (next year): | 10.88% |
AI-Powered INCY Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 74.67%
74.67%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Incyte Corp. (INCY)
Tray Thomas
Sell
Principal Accounting Officer
INCY Dec 19, 2025
Avg Cost/Share
$100.00
Shares
2,774
Total Value
$277,400.00
Owned After
22,973
SEC Form 4
Tray Thomas
Sell
Principal Accounting Officer
INCY Dec 18, 2025
Avg Cost/Share
$98.25
Shares
600
Total Value
$58,950.00
Owned After
22,973
SEC Form 4
Morrissey Michael James
Sell
EVP, Head of Tech. Operations
INCY Dec 17, 2025
Avg Cost/Share
$97.26
Shares
4,323
Total Value
$420,454.98
Owned After
27,507
SEC Form 4
Morrissey Michael James
Sell
EVP, Head of Tech. Operations
INCY Dec 16, 2025
Avg Cost/Share
$97.36
Shares
54,008
Total Value
$5,254,546.61
Owned After
27,507
Stein Steven H
Sell
EVP & Chief Medical Officer
INCY Dec 2, 2025
Avg Cost/Share
$102.51
Shares
20,105
Total Value
$2,060,963.55
Owned After
63,129
SEC Form 4
Stein Steven H
Sell
EVP & Chief Medical Officer
INCY Dec 1, 2025
Avg Cost/Share
$102.96
Shares
2,559
Total Value
$263,474.64
Owned After
63,129
SEC Form 4
Tray Thomas
Sell
Principal Accounting Officer
INCY Nov 24, 2025
Avg Cost/Share
$103.00
Shares
600
Total Value
$61,800.00
Owned After
22,973
SEC Form 4
Tray Thomas
Sell
Principal Accounting Officer
INCY Nov 21, 2025
Avg Cost/Share
$102.00
Shares
169
Total Value
$17,238.00
Owned After
22,973
SEC Form 4
Denton Sheila A.
Sell
EVP & General Counsel
INCY Nov 17, 2025
Avg Cost/Share
$104.36
Shares
278
Total Value
$29,012.08
Owned After
26,569
SEC Form 4
Hoppenot Herve
Sell
Director
INCY Nov 10, 2025
Avg Cost/Share
$105.46
Shares
187,500
Total Value
$19,773,750.00
Owned After
329,646
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Tray Thomas | INCY | Principal Accounting Officer | Dec 19, 2025 | Sell | $100.00 | 2,774 | $277,400.00 | 22,973 | |
| Tray Thomas | INCY | Principal Accounting Officer | Dec 18, 2025 | Sell | $98.25 | 600 | $58,950.00 | 22,973 | |
| Morrissey Michael James | INCY | EVP, Head of Tech. Operations | Dec 17, 2025 | Sell | $97.26 | 4,323 | $420,454.98 | 27,507 | |
| Morrissey Michael James | INCY | EVP, Head of Tech. Operations | Dec 16, 2025 | Sell | $97.36 | 54,008 | $5,254,546.61 | 27,507 | |
| Stein Steven H | INCY | EVP & Chief Medical Officer | Dec 2, 2025 | Sell | $102.51 | 20,105 | $2,060,963.55 | 63,129 | |
| Stein Steven H | INCY | EVP & Chief Medical Officer | Dec 1, 2025 | Sell | $102.96 | 2,559 | $263,474.64 | 63,129 | |
| Tray Thomas | INCY | Principal Accounting Officer | Nov 24, 2025 | Sell | $103.00 | 600 | $61,800.00 | 22,973 | |
| Tray Thomas | INCY | Principal Accounting Officer | Nov 21, 2025 | Sell | $102.00 | 169 | $17,238.00 | 22,973 | |
| Denton Sheila A. | INCY | EVP & General Counsel | Nov 17, 2025 | Sell | $104.36 | 278 | $29,012.08 | 26,569 | |
| Hoppenot Herve | INCY | Director | Nov 10, 2025 | Sell | $105.46 | 187,500 | $19,773,750.00 | 329,646 |
Latest Incyte Corp. News
INCY Breaking Stock News: Dive into INCY Ticker-Specific Updates for Smart Investing
Compare INCY vs Leading Stocks
See how INCY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "INCY Incyte Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.